

---

## Spago Nanomedical - Tumorad progress

Tumorad-01 is progressing towards the DMC meeting and the study is about to expand the number of patients as well as the number of cancer types represented. The cost base is contained and the recent funding has increased the cash position to SEK 47.7m. Our updated base case is SEK 1.0 (1.0), Bull case SEK 2.6 (2.6) and a Bear Case of SEK 0.2 (0.2).

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Spago Nanomedical - Tumorad progress](#)